Regarding research methodology i want to prepare a question in form of pico model and generate primary objective as opioid consumption and also include secondary objective and i want to generate regarding efficacy of iv dexmedetomidine infusion on opioid consumption in patients undergoing laparoscopic surgery
Reading File
Finding Sources
Searching PubMed
dexmedetomidine intravenous opioid consumption laparoscopic surgery
Searching the Web
PICO model dexmedetomidine IV infusion opioid consumption laparoscopic surgery research methodology
Reading File
Reading File
Searching PubMed
dexmedetomidine perioperative opioid sparing analgesia
I now have excellent material from the medical library, PubMed, and web sources to construct a thorough, well-supported PICO framework. Here is the complete structured response:
PICO Research Question: Efficacy of IV Dexmedetomidine Infusion on Opioid Consumption in Laparoscopic Surgery
PICO Framework
| Element | Component | Detail |
|---|---|---|
| P | Population | Adult patients (≥18 years) undergoing elective laparoscopic surgery under general anesthesia |
| I | Intervention | Intravenous dexmedetomidine infusion (continuous perioperative infusion, with or without a loading dose) |
| C | Comparison | Placebo (normal saline infusion) or standard opioid-based analgesia without dexmedetomidine |
| O | Outcome | Total perioperative opioid consumption (measured in morphine milligram equivalents, MME) |
PICO Question (Structured)
"In adult patients undergoing laparoscopic surgery (P), does intravenous dexmedetomidine infusion (I), compared to placebo or standard opioid-based analgesia (C), reduce total perioperative opioid consumption (O)?"
Primary Objective
To evaluate the efficacy of intravenous dexmedetomidine infusion on total perioperative opioid consumption (measured in morphine milligram equivalents) in adult patients undergoing laparoscopic surgery.
- Measurement tool: Total opioid dose (intraoperative + first 24 hours postoperative), expressed in MME
- Time points: Intraoperative period, PACU (0-2 h), early postoperative (0-12 h), and late postoperative (12-24 h)
Rationale: IV dexmedetomidine, a highly selective alpha-2 adrenergic agonist, reduces sympathetic outflow and modulates pain transmission at the spinal dorsal horn, providing opioid-sparing analgesia. A recent meta-analysis (PMID: 41527017, Sun et al., 2026) and an earlier meta-analysis specific to laparoscopic cholecystectomy (PMC8512507) both demonstrated that IV dexmedetomidine significantly reduces opioid consumption in the first 24 h postoperatively (WMD -19.17 MME; 95% CI -30.29 to -8.04; p = 0.0007). The textbook Barash, Cullen & Stoelting's Clinical Anesthesia, 9e confirms that "dexmedetomidine infusion during bariatric surgery reduces fentanyl use, PONV, and recovery room length of stay" and Miller's Anesthesia, 10e notes that adjunct analgesics including dexmedetomidine "will decrease opioid requirements and thereby opioid-induced side effects."
Secondary Objectives
1. Postoperative Pain Intensity
- Measure: Numerical Rating Scale (NRS, 0-10) or Visual Analogue Scale (VAS, 0-100 mm)
- Time points: 30 min, 2 h, 6 h, 12 h, and 24 h postoperatively
- Rationale: Pain reduction is the mechanism through which opioid sparing is achieved; VAS scores allow quantification of analgesic efficacy independent of drug consumption.
2. Time to First Analgesic Request (Analgesic Duration)
- Measure: Time in minutes from end of surgery to first patient request for rescue analgesia
- Rationale: The meta-analysis by Wang et al. (PMC8512507) found dexmedetomidine significantly prolonged time to first analgesic request (WMD +38.90 min; 95% CI 0.88-76.93; p = 0.04), suggesting sustained analgesic benefit.
3. Incidence of Postoperative Nausea and Vomiting (PONV)
- Measure: Incidence (%) using a standardized PONV scale (e.g., Bellville score or Rhodes Index); need for antiemetic rescue
- Rationale: PONV is a major complication of laparoscopic surgery and is worsened by opioid use. Dexmedetomidine has been shown to reduce PONV (OR 0.49; 95% CI 0.27-0.89; p = 0.02).
4. Hemodynamic Stability
- Measure: Heart rate (HR) and mean arterial pressure (MAP) at defined intraoperative intervals (baseline, post-induction, pneumoperitoneum, extubation, PACU)
- Rationale: Laparoscopic surgery causes significant sympathetic stimulation during CO2 insufflation. Dexmedetomidine blunts this response via central alpha-2 receptor activation.
5. Rescue Analgesic Consumption
- Measure: Total dose of rescue opioid (e.g., morphine/fentanyl in MME) administered in PACU and first 24 h
- Rationale: Captures analgesic adequacy independent of scheduled dosing.
6. Quality of Recovery
- Measure: QoR-15 score at 24 h postoperatively
- Rationale: A validated 15-item scale assessing emotional state, physical comfort, psychological support, physical independence, and pain - gives a holistic picture of recovery quality.
7. Adverse Effects of Dexmedetomidine
- Measure: Incidence of bradycardia (HR <50 bpm), hypotension (MAP <60 mmHg or >20% drop from baseline), excessive sedation (Ramsay Sedation Scale >4), and respiratory depression
- Rationale: Safety profile is critical; dose-dependent cardiovascular effects are the primary concern with dexmedetomidine infusion.
8. Time to Discharge / Hospital Length of Stay
- Measure: Duration from end of surgery to PACU discharge (in minutes) and total hospital stay (in hours/days)
- Rationale: Reduced opioid-related side effects and better pain control may accelerate discharge and functional recovery.
Study Design Recommendation
| Parameter | Recommendation |
|---|---|
| Design | Double-blind, placebo-controlled Randomized Controlled Trial (RCT) |
| Allocation | Computer-generated block randomization with concealed allocation |
| Blinding | Patient, anesthesiologist, and outcome assessor (triple-blind) |
| Sample size | Based on primary outcome (opioid consumption, MME); use pilot data or published WMD of ~19 MME with SD ~30 |
| Intervention dose | Loading dose: 0.5-1 mcg/kg over 10 min before induction; Maintenance: 0.2-0.7 mcg/kg/h until 30 min before end of surgery |
| Primary endpoint | Total opioid (MME) from induction to 24 h postoperatively |
Key Supporting Literature
- Sun et al. (2026) - Meta-analysis, dexmedetomidine opioid-sparing - PMID 41527017 (most recent systematic review + meta-analysis)
- Wang et al. (2021) - Meta-analysis, laparoscopic cholecystectomy - WMD -19.17 MME in 24 h, PONV OR 0.49
- Shankar et al. (2022) - RCT, nebulized vs. IV dexmedetomidine in laparoscopic surgery - PMID 35483678
- Xu et al. (2021) - RCT, dexmedetomidine in laparoscopic hysterectomy - PMID 34348668
- Barash, Cullen & Stoelting's Clinical Anesthesia, 9e, Chapter on Laparoscopic Surgery - Pharmacologic Adjuncts
- Miller's Anesthesia, 10e, Chapter on Induction of Anesthesia
Summary: The PICO question targets a clearly defined population (adults, laparoscopic surgery), a specific quantifiable intervention (IV dexmedetomidine infusion with defined dosing), a standard comparator (saline/opioid-based anesthesia), and a primary outcome with an established measurement scale (MME opioid consumption). The secondary objectives expand to safety, pain scores, PONV, hemodynamics, and quality of recovery - providing a well-rounded research framework suitable for an RCT or systematic review protocol.
Finer and smart in research methodology
Searching PubMed
dexmedetomidine intravenous opioid consumption laparoscopic surgery
Searching the Web
FINER criteria PICO research question anesthesia clinical trial methodology 2024
Searching PubMed
dexmedetomidine opioid sparing laparoscopic surgery analgesia
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC6691636
I now have everything needed for a refined, academically rigorous PICOT + FINER framework. Here is the complete upgraded version:
PICOT + FINER Research Framework
Efficacy of IV Dexmedetomidine Infusion on Opioid Consumption in Laparoscopic Surgery
Part I - PICOT Question (Extended PICO with Time Frame)
The PICOT framework is the gold-standard tool for structuring interventional research questions in anesthesia, as established by Thabane et al. and endorsed by the Indian Journal of Anaesthesia (PMID 31462805). The T (Time frame) element is the most commonly omitted component and must be explicitly defined.
| PICOT Element | Definition | Application to This Study |
|---|---|---|
| P - Population | Who are the participants? Include inclusion & exclusion specifiers | Adult patients (18-65 years), ASA physical status I-III, scheduled for elective laparoscopic surgery under general anesthesia (e.g., cholecystectomy, hysterectomy, colectomy) |
| I - Intervention | What is being tested, with dose and route | IV dexmedetomidine: loading dose 0.5-1 mcg/kg over 10 min before induction, followed by continuous infusion 0.2-0.7 mcg/kg/h intraoperatively until 30 min before skin closure |
| C - Comparator | What is the control condition | Equivalent volume of normal saline (0.9% NaCl) infusion - placebo-controlled, double-blind |
| O - Outcome | Primary measurable endpoint | Total perioperative opioid consumption (intraoperative + 24 h postoperative) expressed in Morphine Milligram Equivalents (MME) |
| T - Time frame | When outcomes are measured + study duration | Intraoperative period + 0-2 h (PACU) + 2-24 h (ward); recruitment over 12-18 months |
Final PICOT Research Question
"In adult patients (ASA I-III) undergoing elective laparoscopic surgery under general anesthesia (P), does a perioperative intravenous dexmedetomidine infusion (loading 0.5-1 mcg/kg + maintenance 0.2-0.7 mcg/kg/h) (I), compared to an equivalent volume of normal saline placebo (C), reduce total perioperative opioid consumption measured in morphine milligram equivalents over 24 hours postoperatively (O), assessed from the time of induction through 24 hours after surgery (T)?"
Part II - FINER Criteria Appraisal
The FINER criteria (Hulley et al.) act as a validity filter - applied after framing PICOT to ensure the question is worth pursuing. Every element must be justified with evidence.
F - Feasible
| Sub-criterion | Assessment |
|---|---|
| Sample size attainability | Laparoscopic procedures are among the most common surgeries globally; recruitment is highly feasible in any tertiary surgical center |
| Intervention practicality | IV dexmedetomidine (Precedex/generic) is a licensed, available drug with a well-defined dosing protocol and continuous infusion pump infrastructure already in place in operation theaters |
| Outcome measurability | MME is a validated, standardized unit for opioid quantification; NRS/VAS pain scores are routinely recorded in PACU |
| Research team expertise | Anesthesiologists and anesthesia research nurses can conduct this within existing perioperative workflow without additional staffing |
| Budget | Low-cost intervention (generic dexmedetomidine ~$5-15/vial); primary data collection within institutional resources |
| Pilot study option | A 20-patient pilot can validate feasibility, measure SD of MME for sample size calculation, and test blinding |
I - Interesting
| Dimension | Justification |
|---|---|
| Clinical relevance | Opioid-related adverse effects (PONV, respiratory depression, ileus, chronic opioid dependence) remain the dominant source of postoperative morbidity in laparoscopic patients |
| Investigator perspective | The opioid-sparing movement and Enhanced Recovery After Surgery (ERAS) protocols have made this a high-priority research domain for anesthesiologists and surgeons alike |
| Patient perspective | Patients undergoing laparoscopic surgery expect fast recovery; reducing opioids directly shortens PACU stay and improves satisfaction |
| Payer/systems perspective | Reduced opioid use lowers pharmacy costs, PONV management costs, and length of stay |
N - Novel
This is where the research gap is defined. Novelty does not require a completely unstudied topic - it requires filling a specific gap in existing knowledge.
What is already known:
- A 2021 meta-analysis (Wang et al., PMC8512507) of 12 RCTs (n=967) in laparoscopic cholecystectomy found IV dexmedetomidine significantly reduced 24-h opioid consumption (WMD -19.17 MME; 95% CI -30.29 to -8.04; p=0.0007)
- A 2026 meta-analysis (Sun et al., PMID 41527017) confirmed opioid-sparing effects across multiple surgical settings
- RCTs exist in bariatric laparoscopy (Tufanogullari et al., PMID 18499604) and gynecological laparoscopy (Wang et al., PMID 27175680)
Remaining research gaps (novel angles to pursue):
- Dose-response relationship - optimal dexmedetomidine infusion rate for maximal opioid sparing with minimal hemodynamic side effects remains undefined
- Laparoscopy type specificity - most evidence is in cholecystectomy and bariatric surgery; evidence in colorectal, urological, or gynecological laparoscopy is sparse
- Infusion timing - whether starting infusion before induction vs. after induction affects intraoperative vs. postoperative opioid consumption differently is under-studied
- ERAS context - dexmedetomidine's role when embedded within a full ERAS protocol (multimodal analgesia + regional blocks) has not been consistently studied
- Quality of recovery - most trials report pain scores/opioid MME but do not use validated QoR-15 scores as an endpoint
- Long-term opioid use - no studies have tracked whether intraoperative dexmedetomidine infusion reduces opioid prescriptions beyond 24 hours
Novelty statement for your protocol: "While prior meta-analyses confirm dexmedetomidine's opioid-sparing potential in laparoscopic cholecystectomy, high heterogeneity (I² = 97%) across existing trials and absence of dose-standardized, QoR-15-validated evidence in mixed laparoscopic surgery populations creates a clear gap that this trial addresses."
E - Ethical
| Ethical Dimension | Assessment |
|---|---|
| Risk-benefit ratio | Dexmedetomidine is FDA/EMA-approved for ICU sedation and widely used off-label perioperatively; established safety profile. Primary risks (bradycardia, hypotension) are manageable and monitored intraoperatively as standard of care |
| Equipoise | Genuine clinical uncertainty exists about optimal dosing and generalizability across laparoscopic procedure types - ethical justification for a placebo-controlled trial is valid |
| Placebo use | Patients in the control group receive standard-of-care opioid analgesia, not withheld treatment - a saline placebo replaces only the dexmedetomidine, not analgesia itself |
| Informed consent | Standard written informed consent with clear disclosure of dexmedetomidine's hemodynamic effects |
| Data safety | Pre-specified stopping rules: if >5% of dexmedetomidine patients develop hemodynamic instability requiring vasopressors, an interim safety analysis triggers |
| Ethics committee | Institutional Review Board (IRB)/Ethics Committee approval required; registration on ClinicalTrials.gov (NCT) or CTRI mandatory before first enrollment |
R - Relevant
| Stakeholder | Relevance |
|---|---|
| Clinical practice | Results directly inform whether dexmedetomidine should be incorporated into standard ERAS analgesia bundles for laparoscopic surgery |
| Anesthesia guidelines | Current ERAS Society and SAMBA guidelines acknowledge opioid-sparing strategies but do not give dexmedetomidine a specific recommendation grade for laparoscopic procedures |
| Public health | With the global opioid epidemic context, any validated strategy to reduce perioperative opioid exposure has direct public health significance |
| Surgical outcomes | Reduced PONV and faster return of bowel function directly reduce hospital length of stay and readmission rates |
| Research field | Adds a standardized, QoR-15-validated RCT to a meta-analytic base currently plagued by high heterogeneity - will improve future pooled estimates |
Part III - Primary and Secondary Objectives (Formally Worded)
Primary Objective
"To determine whether perioperative intravenous dexmedetomidine infusion (0.5 mcg/kg loading + 0.4 mcg/kg/h maintenance) reduces total perioperative opioid consumption, expressed in morphine milligram equivalents (MME), over the 24-hour period following elective laparoscopic surgery compared to placebo."
Secondary Objectives
| # | Objective | Measurement Tool | Time Points |
|---|---|---|---|
| 1 | To compare postoperative pain intensity between groups | NRS (0-10) | 30 min, 2 h, 6 h, 12 h, 24 h post-op |
| 2 | To assess time to first rescue analgesic request | Clock time (minutes from PACU admission) | Continuous monitoring in PACU |
| 3 | To evaluate incidence and severity of PONV | PONV impact scale (0-6) + antiemetic rescue dose | 0-6 h and 6-24 h post-op |
| 4 | To assess intraoperative hemodynamic stability | HR and MAP at 8 defined time points | Baseline, post-induction, insufflation, every 15 min intraoperatively, extubation, PACU |
| 5 | To measure quality of recovery | QoR-15 validated questionnaire (score 0-150) | 24 h postoperatively |
| 6 | To document adverse effects attributable to dexmedetomidine | Bradycardia (<50 bpm), hypotension (MAP <65 mmHg), excessive sedation (Ramsay >4), shivering | Continuous intraoperative + PACU |
| 7 | To compare time to PACU discharge readiness | Modified Aldrete Score ≥9 | Time from PACU admission |
| 8 | To compare total hospital length of stay | Hours from end of surgery to discharge | Discharge day |
Part IV - Hypothesis Statement
Null Hypothesis (H₀): There is no significant difference in total 24-hour perioperative opioid consumption (MME) between patients receiving IV dexmedetomidine infusion and those receiving placebo during elective laparoscopic surgery.
Alternative Hypothesis (H₁): Perioperative IV dexmedetomidine infusion significantly reduces total 24-hour perioperative opioid consumption (MME) compared to placebo in patients undergoing elective laparoscopic surgery.
Expected direction: Two-tailed test; superiority design based on prior WMD of -19.17 MME (95% CI -30.29 to -8.04) from the existing meta-analytic evidence.
Summary Schematic
BROAD TOPIC
Perioperative pain management in laparoscopic surgery
↓
FINER FILTER (pre-design)
Is it Feasible? Interesting? Novel? Ethical? Relevant?
↓
PICOT QUESTION (structured)
P → Adult ASA I-III patients, elective laparoscopic surgery
I → IV Dexmedetomidine (load + infusion)
C → Normal saline placebo
O → Total opioid consumption (MME) at 24 h [PRIMARY]
+ Pain scores, PONV, hemodynamics, QoR-15 [SECONDARY]
T → Induction through 24 h postoperatively
↓
OBJECTIVES
Primary: Opioid consumption (MME)
Secondary: Pain, PONV, hemodynamics, QoR-15, safety
↓
HYPOTHESIS → RCT Protocol → Sample Size → Ethics → Registration
Key Evidence Base:
- Sun et al., 2026 - Systematic review + meta-analysis, dexmedetomidine opioid-sparing (PMID 41527017) - most current evidence
- Wang et al., 2021 - Meta-analysis, laparoscopic cholecystectomy specific - WMD -19.17 MME, forms basis for sample size calculation
- Zhang et al., 2022 - Meta-analysis, bariatric laparoscopy (PMID 35422388)
- Tufanogullari et al., 2008 - Landmark RCT, dexmedetomidine in laparoscopic bariatric surgery (PMID 18499604)
- Shankar et al., 2022 - RCT, IV dexmedetomidine vs. nebulized in laparoscopic surgery (PMID 35483678)
- PICOT+FINER methodology - Indian Journal of Anaesthesia, 2019 (PMID 31462805)
This is a shared conversation. Sign in to Orris to start your own chat.